Nuvectis Pharma (NVCT) said Friday it closed its public offering of 2.7 million shares, with the underwriter exercising in full the option to buy 405,000 additional shares at $5 per share, boosting gross proceeds to about $15.5 million.
The company said it expects to use the net proceeds from the offering to continue clinical development of its NXP800 and NXP900 product candidates, hire additional personnel, and for capital expenditures and other general corporate purposes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。